Features

  • Proteins, such as Insulin and SARS-CoV-2 RBD, are selected to develop therapeutic candidates
  • Fc region selected for species-specificity
  • Saccharides enhance or suppress immune interaction
  • Insulin mutations and c-peptide composition control insulin receptor activity
  • Proprietary modifications reduce immunogenicity
  • Linker moeity can be “tuned” for manufacturability